1) American Psychiatric Association(原著), 日本精神神経学会(日本語版用語監修), 高橋三郎, 他(監訳), 染矢俊幸, 他(訳):DSM-5 精神疾患の診断・統計マニュアル. 医学書院, 2014
2) 森 悦朗, 他:神経疾患患者における日本語版Mini-Mental State テストの重要性. 神心理 1985;1:82-90
3) 加藤伸司, 他:改訂長谷川式簡易知能評価スケール(HDS-R)の作成. 老年精医誌 1991;2:1339-1347
4) 本間 昭, 他:Alzheimer's disease assessment scale(ADAS). 日臨 2003;61(増9):129-132
5) Onoda K, et al.:Validation of a new mass screening tool for cognitive impairment:Cognitive Assessment for Dementia, iPad version. Clin Interv Aging 2013;8:353-360
6) Yesavage JA, et al.:Development and validation of a geriatric depression screening scale:a preliminary report. J Psychiatr Res 1982;17:37-49
7) 鳥羽研二(監):高齢者総合的機能評価ガイドライン. 厚生科学研究所, 2003
8) McKeith IG, et al.:Diagnosis and management of dementia with Lewy bodies:Fourth report of the DLB consortium. Neurology 2017;89:88-100
9) Neary D, et al.:Frontotemporal lobar degeneration:a consensus on clinical diagnostic criteria. Neurology 1998;51:1546-1554
10) 鈴木みな子:目からウロコの認知症対策. 主婦の友社(編):認知症 家族を救う対策集. 主婦の友社, 2011:82-98
11) 朝田 隆:認知症でみられる非認知症状とその対応. 神経内科 2010;72(増6):138-143
12) 川嵜弘詔(監):せん妄の診断・治療. 2007 http://www.med.kyushu-u.ac.jp/psychiatry/_userdata/delirium.pdf
13) 日本神経学会(監), 「認知症疾患治療ガイドライン」作成合同委員会(編):認知症疾患治療ガイドライン2010 コンパクト版2012. 医学書院, 2012
14) 工藤千秋, 他:保湿剤の塗布がリバスチグミン貼付剤の皮膚症状を軽減させる~皮脂欠乏症を伴う認知症患者に保湿剤を貼付1週間前から塗布する有用性の検討~. 日早期認知症会誌 2013;6:98-102
15) Silverberg GD, et al.:Assessment of low-flow CSF drainage as a treatment for AD:results of a randomized pilot study. Neurology 2002;59:1139-1145
16) 大槻美佳:言語機能の局在地図. 高次脳機能研 2007;27:231-243
17) Erickson KI, et al.:Aerobic fitness is associated with hippocampal volume in elderly humans. Hippocampus 2009;19:1030-1039
18) Yu BP, et al.:Nutritional influences on aging of Fischer 344 rats:1. Physical, metabolic, and longevity characteristics. J Gerontol 1985;40:657-670
19) Colman RJ, et al.:Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 2009;325:201-204
20) Kenyon C, et al.:A C. elegans mutant that lives twice as long as wild type. Nature1993;366:461-464
21) Imai S, et al.:Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000;403:795-800
22) Mizoguchi K, et al.:Stress induces neuronal death in the hippocampus of castrated rats. Neurosci Lett 1992;138:157-160
23) 日本老年医学会(編):老年医学テキスト 改訂第3版. メジカルビュー社, 2008
24) 津軽谷 恵:在宅高齢者と介護老人保健施設入所者の主観的QOLについて-Visual Analogue Scaleを用いて-. 秋田大保健紀 2003;11:46-54
25) 高齢者糖尿病の治療向上のための日本糖尿病学会と日本老年医学会の合同委員会:高齢者糖尿病の血糖コントロール目標について. 2016 http://www.jds.or.jp/modules/important/index.php?content_id=66
26) Carriere I, et al.:Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population:the 3-city study. Arch Intern Med 2009;169:1317-1324
27) Rudolph JL, et al.:The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 2008;168:508-513
28) Mizukami K, et al.:A randomized cross-over study of a traditional Japanese medicine(kampo), yokukansan, in the treatment of the behavioural and psychological symptoms of dementia. Int J Neuropsychopharmacol 2009;12:191-199
29) Terasawa K, et al.:Choto-san in the treatment of vascular dementia:a double-blind, placebo-controlled study. Phytomedicine 1997;4:15-22
30) Iwasaki K, et al.:A randomized, double-blind, placebo-controlled clinical trial of the Chinese herbal medicine "ba wei di huang wan" in the treatment of dementia. J Am Geriatr Soc 2004;52:1518-1521
31) 荒井啓行, 他:アルツハイマー病の薬物療法-加味温胆湯による治療介入の試み. 日老医誌 2000;37:212-215
32) Maruyama M, et al.:Benefits of combining donepezil plus traditional Japanese herbal medicine on cognition and brain perfusion in Alzheimer's disease:a 12-week observer-blind, donepezil monotherapy controlled trial. J Am Geriat Soc 2006;54:869-871
33) 認知症の早期発見, 予防・治療研究会 https://dscm-ken.jp/
34) Kudoh C, et al.:Effects of ferulic acid and Angelica archangelica extract (Feru-guard(R)) on mild cognitive impairment:A multicenter, randomized, double-blind, placebo-controlled prospective trial. J Alzheimers Dis Rep 2020;4:393-398
35) 河村 満(専門編集), 辻 省次(総編集):認知症 神経心理学的アプローチ(アクチュアル 脳・神経疾患の臨床). 中山書店, 2012:4
36) 滝浦孝之:三宅式記銘力検査(東大脳研式記銘力検査)の標準値:文献的検討. 広島修大論集第48巻第1号(人文), 2007:215-272
37) 原 寛美:リバーミード行動記憶検査(RBMT). J Clin Rehabil 2009;18:346-351
38) Mahoney FI, et al.:Functional evaluation:the Barthel index. Md State Med J 1965;14:61-65
39) Lawton MP, et al.:Assessment of older people:Self maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-186
40) 岡田和悟, 他:やる気スコアを用いた脳卒中後の意欲低下の評価. 脳卒中 1998;20:318-323
41) Johonson JK, et al.:Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch Neurol 1999;56:1233-1239
42) Alladi S, et al.:Focal cortical presentations of Alzheimer's disease. Brain 2007;130:2636-2645
43) McMonagle P, et al.:The cognitive profile of posterior cortical atrophy. Neurol 2006;66:331-338
44) Alzforum http://www.alzforum.org
45) Corder EH, et al.:Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-923
46) Jack CR Jr, et al.:Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-128
47) Sperling RA, et al.:Toward defining the preclinical stages of Alzheimer's disease:Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheim Dement 2011;7:280-292
48) Asada T, et al.:Development of informant-reported or self-reported MCI-J questionnaire. Int J Geriatr Psychiatry 2022;37. doi:10.1002/gps.5773
49) Sieben A, et al.:The genetics and neuropathology of frontotemporal lobar degeneration. Acta Neuropathol 2012;124:353-372
50) Iijima M, et al.:A distinct familial presenile dementia with a novel missense mutation in the tau gene. NeuroReport 1999;10:497-501
51) Crary JF, et al.:Primary age-related tauopathy(PART):a common pathology associated with human aging. Acta Neuropathol 2014;128:755-766
52) Nelson PT, et al.:Limbic-predominant age-related TDP-43 encephalopathy(LATE):consensus working group report. Brain 2019;142:1503-1527